GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both “next generation” drugs involved flunk clinical trials.
Source: FierceBiotech
You may also like
This common pesticide may be quietly wiping out future...
Boehringer Ingelheim’s Jascayd approved by MHRA for...
Ipsen to acquire Memo Therapeutics in deal worth more...
Macrophage Membrane-Derived Nanoparticles Shows...
Epigenomic Analysis Uncovers New AML Subgroups and...
GSK, Hansoh ADC extends survival in lung cancer study
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.